ADMA Biologics (NASDAQ: ADMA) reported Q4 EPS of ($0.08), $0.11 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $73.9 million versus the consensus estimate of $72.15 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.